2022 State of Digital Lab Transformation in Biopharma
As biopharma players seek cloud benefits, this Pharma IQ report reveals how the industry could avoid wasting millions of dollars on new therapeutics due to inefficiencies in data management and digital lab connectivity
Add bookmark
Pharma’s adoption of cloud and other modern IT technologies has often lagged behind other industries. As the pace of change accelerates due to business challenges and black swan events, however, cloud platforms – in tandem with breakout technologies like machine learning (ML) – are now enabling organizations within the field to meet their challenges and transform their businesses.
This exclusive Pharma IQ report, produced in association with R&D data cloud provider TetraScience, examines where biopharma organizations currently stand in their approaches to cloud technologies, according to the results of the 2022 State of Digital Lab Transformation in Biopharma Survey.
This report reveals the views of industry insiders addressing how their organizations are strategizing their approach to cloud adoption, digital lab connectivity, FAIR data and AI/ML solutions.
Download this exclusive report to find out:
- How bench scientists and data scientists, who are spending approximately 50 percent of their time cleansing, enriching and curating data, can reclaim time for R&D.
- What the true cost of not replatforming to the cloud using FAIR (Findable, Accessible, Reusable, and Interoperable) principles is to the biopharma industry.
